← Back to Search

Other

Angiotensin Converting Enzyme Exposed for High Blood Pressure

Phase 4
Waitlist Available
Led By Craig J Railton, MD, PhD
Research Sponsored by Lawson Health Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately every 5 minutes for 6 hours
Awards & highlights

Study Summary

It is controversial whether or not patients whose Renin Angiotensin System is blocked for the treatment of hypertension suffer increased risk when undergoing surgery and anaesthesia. The investigators wish to test the hypothesis: Blockade of the Renin Angiotensin System causes altered dose response under general anaesthesia in a dose dependant manner. The investigators wish to look for altered responses across the usual anaesthetic dosing range as measured by blood pressure and heart responses.

Eligible Conditions
  • High Blood Pressure

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately every 5 minutes for 6 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately every 5 minutes for 6 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Systemic Vascular Resistance Index (SVRI)
Secondary outcome measures
Cardiac Index (CI)
Cardiac Output (CO)
Central Venous Pressure
+5 more

Trial Design

3Treatment groups
Experimental Treatment
Group I: Non ACE/ARB ExposedExperimental Treatment1 Intervention
Sevoflurane/oxygen/air/nitrous oxide Hypertensive patients not exposed to angiotensin converting enzyme inhibitors or Angiotensin receptor blocking agents will be put into this arm.
Group II: Angiotensin Receptor Blocker ExposedExperimental Treatment1 Intervention
Sevoflurane/oxygen/air/nitrous oxide Hypertensive patients exposed to Angiotensin Receptor Blocking Agents (ARBs). Preoperative Exposure to any of the following Angiotensin II Receptor Blocking Agents Losartan(Cozaar) Candesartan (Atacand) Valsartan (Diovan) Irbesartan (Avapro) Telmisartan (Micardis) Eprosartan (Teveten) Olemisartan (Benicar) Azilsartan (Edarbi)
Group III: Angiotensin Converting Enzyme ExposedExperimental Treatment1 Intervention
Sevoflurane/oxygen/air/nitrous oxide Hypertensive patients exposed to Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)will make up this arm. Preoperative Exposure to any of the following Angiotensin Converting Enzyme Inhibitors Enalapril (Vasotec/Renitec) Ramipril (Altace/Prilace/Ramace/Ramiwin/Triatec/Tritace) Quinapril (Accupril) Perindopril (Coversyl/Aceon) Lisinopril (Listril/Lopril/Novatec/Prinivil/Zestril) Benazepril (Lotensin) Imidapril (Tanatril) Zofenopril (Zofecard) Trandolapril (Mavik/Odrik/Gopten) Fosinopril (Fositen/Monopril)

Find a Location

Who is running the clinical trial?

Lawson Health Research InstituteLead Sponsor
659 Previous Clinical Trials
413,652 Total Patients Enrolled
University of Western Ontario, CanadaOTHER
164 Previous Clinical Trials
319,166 Total Patients Enrolled
Craig J Railton, MD, PhDPrincipal InvestigatorLawson Health Research Institute

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Is There an Adverse Drug Reaction Between Renin-Angiotensin System Blockade and Inhaled Anesthetics
Craig Railton 2012. "Is There an Adverse Drug Reaction Between Renin-Angiotensin System Blockade and Inhaled Anesthetics". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01715584.
All > Anesthesia
~6 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top